To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

June 18, 2024

Study for Newly Diagnosed PCNSL Patients

For Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Logos for PROSPECT and ONO Pharm

Sites are still actively recruiting patients with newly diagnosed Primary Central Nervous System Lymphona (PCNSL) for Part B of the PROSPECT Study. This study is for patients who have not received prior anti-tumor treatments for PCNSL.

This is an Open-label Phase II Study to investigate the efficacy, safety, and pharmacokinetics of Tirabrutinib in patients with PCNSL. The trial number is  NCT04947319. Sites are recruiting for this study across the United States.

For more information on inclusion/exclusion criteria and active sites, click the button below and fill out the Interest Form. The End Brain Cancer Initiative's Clinical Research Coordinator/Patient Navigator will contact you to help you figure out if this study may be a good fit for you and if so, will “DIRECTLY CONNECT” you to the site and specialist closest to where you live.

Sponsor logos

EBCI app on cell phone


Scan or click the QR code to download the App now!


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram